Hatteras — Full Portfolio
6 tracked investments · listed companies and verified rows first
Clearside Biomedical is an intellectual property holding, investment, and commercialization company focused on its suprachoroidal space (SCS) ocular drug-delivery platform and microinjector technology.
BiotechHealthtechMedical DevicesAlpharetta, US
Mark Prausnitz(Director)inCharles Deignan(Executive Officer)Glenn Noronha(Executive Officer)inDaniel H. White(Executive Officer, Director)in
BoardEvgeny Zaytsev(Director)Derek Yoon(Director)in
Board seatClay B. Thorp· per SEC Form D · $320K raise · filed Oct 2016
Co-investorsHEALTHCARE ROYALTY PARTNERSMountain Group CapitalSolasta VenturesHatteras Venture Partners
Incyclix Bio develops precision cancer treatments targeting the CDK family of enzymes to restore cell cycle control in tumors, including CDK targets beyond CDK4/6 such as CDK2.
BiotechHealthtechDurham, US
Patrick Roberts(Executive Officer and member of the Board of Managers.)in
BoardFredric N. Eshelman(Executive Officer and member of the Board of Managers.)Sid Subramony(Member of the Board of Managers.)Norman Sharpless(Member of the Board of Managers.)
Co-investorsCape Fear BioCapitalEshelman Ventures, LLCHatteras Venture Partners
Perfuse Therapeutics develops novel ocular therapies for retinal and glaucoma diseases through drug delivery and formulation platforms.
BiotechHealthtechMedical DevicesSan Francisco, US
Sevgi Gurkan, MD(Founder, Chief Executive Officer, and Member of the Board of Directors)in
BoardChristy Shaffer(Director)Chau Khuong(Director)inSevgi Gurkan(Executive Officer, Director, Promoter)in
Co-investorsOrbiMedAccess BiotechnologyCatalio Capital Management, LPHatteras Venture PartnersLAVLilly Asia Ventures
Santé builds a point-of-sale system designed specifically for liquor retail stores.
AI & Machine LearningEnterprise SoftwareFintechRetail TechSaaSNew York City, US
Darren Fike(Founder)in
Co-investorsBonfire VenturesKima VenturesOperator CollectiveTrail Run CapitalVeridical VenturesY Combinator+2 more
Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets.
AI & Machine LearningBiotechDeep TechDurham, US
Mark A. Hallen(Executive Officer, Director)inMarcel Frenkel(Executive Officer, Director)Damien Petty(Director)inJia Wei Xu(Director)
Co-investorsCape Fear BioCapitalDFJ DragonFundDraper AssociatesDuke Capital PartnersHatteras Venture PartnersAlexandria+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.